Apricoxib: Difference between revisions

Apricoxib
Identifiers
	IUPAC name 4-[2-(4-Ethoxyphenyl)-4-methyl-1H-pyrrol-1-yl]benzenesulfonamide;
CAS Number	162011-90-7;
PubChem CID	9820073;
ChemSpider	7995822;
CompTox Dashboard (EPA)	DTXSID60173502 ;
Chemical and physical data
Formula	C19H20N2O3S
Molar mass	356.4387 g/mol g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCOC1=CC=C(C=C1)C2=CC(=CN2C3=CC=C(C=C3)S(=O)(=O)N)C;
	InChI InChI=1S/C19H20N2O3S/c1-3-24-17-8-4-15(5-9-17)19-12-14(2)13-21(19)16-6-10-18(11-7-16)25(20,22)23/h4-13H,3H2,1-2H3,(H2,20,22,23); Key:JTMITOKKUMVWRT-UHFFFAOYSA-N;

Browse history interactively

← Previous edit Next edit →

Content deleted Content added

VisualWikitext

Inline

Revision as of 08:57, 10 February 2017

Apricoxib is an experimental anticancer drug in Phase II clinical trials. It is a COX-2 inhibitor which improves standard therapy response in molecularly defined models of pancreatic cancer.^[1]

References

^ Kirane, A. (2012). "Apricoxib, a Novel Inhibitor of COX-2, Markedly Improves Standard Therapy Response in Molecularly Defined Models of Pancreatic Cancer". Clinical Cancer Research. 18 (18): 5031–5042. doi:10.1158/1078-0432.CCR-12-0453. PMC 3777527. PMID 22829202.

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.

[1] Kirane, A. (2012). "Apricoxib, a Novel Inhibitor of COX-2, Markedly Improves Standard Therapy Response in Molecularly Defined Models of Pancreatic Cancer". Clinical Cancer Research. 18 (18): 5031–5042. doi:10.1158/1078-0432.CCR-12-0453. PMC 3777527. PMID 22829202.

[1]

@@ Line 15: / Line 15: @@
 | KEGG =
 | ChEBI =
 | ChEMBL =
 <!--Chemical data-->
@@ Line 25: / Line 25: @@
 }}
-'''Apricoxib''' is an experimental anticancer drug in Phase II clinical trials. It is a [[COX-2 inhibitor]] which improves standard therapy response in molecularly defined models of pancreatic cancer.<ref>{{cite journal | doi = 10.1158/1078-0432.CCR-12-0453 | title=Apricoxib, a Novel Inhibitor of COX-2, Markedly Improves Standard Therapy Response in Molecularly Defined Models of Pancreatic Cancer | journal=Clinical Cancer Research | date=2012 | volume=18 | issue=18 | pages=5031–5042 | first=A. | last=Kirane}}</ref>
+'''Apricoxib''' is an experimental anticancer drug in Phase II clinical trials. It is a [[COX-2 inhibitor]] which improves standard therapy response in molecularly defined models of pancreatic cancer.<ref>{{cite journal | doi = 10.1158/1078-0432.CCR-12-0453 | title=Apricoxib, a Novel Inhibitor of COX-2, Markedly Improves Standard Therapy Response in Molecularly Defined Models of Pancreatic Cancer | journal=Clinical Cancer Research | date=2012 | volume=18 | issue=18 | pages=5031–5042 | first=A. | last=Kirane | pmid=22829202 | pmc=3777527}}</ref>
 ==See also==
@@ Line 35: / Line 35: @@
 ==References==
 {{Reflist|2}}
 {{Prostanoidergics}}
@@ Line 42: / Line 41: @@
 [[Category:Sulfonamides]]
 [[Category:Experimental cancer drugs]]
 {{pharma-stub}}